References of "LIFRANGE, Eric"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMyoferlin is a key regulator of EGFR activity in breast cancer.
Turtoi, Andrei ULg; Blomme, Arnaud ULg; Bellahcene, Akeila ULg et al

in Cancer Research (2013)

Myoferlin is a member of the ferlin family of proteins that participate in plasma membrane fusion, repair and endocytosis. While some reports have implicated myoferlin in cancer, the extent of its ... [more ▼]

Myoferlin is a member of the ferlin family of proteins that participate in plasma membrane fusion, repair and endocytosis. While some reports have implicated myoferlin in cancer, the extent of its expression in and contributions to cancer are not well established. In this study, we show that myoferlin is overexpressed in human breast cancers and that it is has a critical role in controlling degradation of the EGFR after its activation and internalization in breast cancer cells. Myoferlin depletion blocked EGF-induced cell migration and epithelial-to-mesenchymal transition. Both effects were induced as a result of impaired degradation of phosphorylated EGFR via dysfunctional plasma membrane caveolae and alteration of caveolin homooligomerization. In parallel, myoferlin depletion reduced tumor development in a chicken chorioallantoic membrane xenograft model of human breast cancer. Considering the therapeutic significance of EGFR targeting, our findings identify myoferlin as an novel candidate function to target for future drug development. [less ▲]

Detailed reference viewed: 47 (7 ULg)
Full Text
Peer Reviewed
See detailEuropean inter-institutional impact study of MammaPrint
CUSUMANO, Giuseppe ULg; Generali, D; Ciruelos, E et al

Poster (2012)

Detailed reference viewed: 22 (1 ULg)
Full Text
Peer Reviewed
See detailNovel comprehensive approach for accessible biomarker identification and absolute quantification from precious human tissues
Turtoi, Andrei ULg; Dumont, Bruno ULg; Greffe, Yannick et al

in Journal of Proteome Research (2011), 10(7), 3160-82

The identification of specific biomarkers obtained directly from human pathological lesions remains a major challenge, because the amount of tissue available is often very limited. We have developed a ... [more ▼]

The identification of specific biomarkers obtained directly from human pathological lesions remains a major challenge, because the amount of tissue available is often very limited. We have developed a novel, comprehensive, and efficient method permitting the identification and absolute quantification of potentially accessible proteins in such precious samples. This protein subclass comprises cell membrane associated and extracellular proteins, which are reachable by systemically deliverable substances and hence especially suitable for diagnosis and targeted therapy applications. To isolate such proteins, we exploited the ability of chemically modified biotin to label ex vivo accessible proteins and the fact that most of these proteins are glycosylated. This approach consists of three successive steps involving first the linkage of potentially accessible proteins to biotin molecules followed by their purification. The remaining proteins are then subjected to glycopeptide isolation. Finally, the analysis of the nonglycosylated peptides and their involvement in an in silico method increased the confident identification of glycoproteins. The value of the technique was demonstrated on human breast cancer tissue samples originating from 5 individuals. Altogether, the method delivered quantitative data on more than 400 potentially accessible proteins (per sample and replicate). In comparison to biotinylation or glycoprotein analysis alone, the sequential method significantly increased the number (≥30% and ≥50% respectively) of potentially therapeutically and diagnostically valuable proteins. The sequential method led to the identification of 93 differentially modulated proteins, among which several were not reported to be associated with the breast cancer. One of these novel potential biomarkers was CD276, a cell membrane-associated glycoprotein. The immunohistochemistry analysis showed that CD276 is significantly differentially expressed in a series of breast cancer lesions. Due to the fact that our technology is applicable to any type of tissue biopsy, it bears the ability to accelerate the discovery of new relevant biomarkers in a broad spectrum of pathologies. [less ▲]

Detailed reference viewed: 59 (25 ULg)
Full Text
Peer Reviewed
See detailTechniques de prélèvements cytologiques en pathologie mammaire
LAMBERT, Chantal ULg; Colin; Delvenne, Philippe ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 261-4

Mammary cytology is part of the breast cancer test. Its accuracy depends on both the sample quality and the cyto-pathologist’s competence. Extracting cells in a liquid environment allows obtaining smears ... [more ▼]

Mammary cytology is part of the breast cancer test. Its accuracy depends on both the sample quality and the cyto-pathologist’s competence. Extracting cells in a liquid environment allows obtaining smears in less hemorrhagic thin layers, containing more cells and with less interference with the fixation artefact. This technique keeps materiel for further immunocytochemistry and cell biology studies if needed. It will be especially useful in automated analysis. [less ▲]

Detailed reference viewed: 51 (1 ULg)
Full Text
Peer Reviewed
See detailAccelerated partial breast irradiation: state of the art
COUCKE, Philippe ULg; JANSEN, Nicolas ULg; JANVARY, Zsolt Levente ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2011), 5(1), 3-7

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for ... [more ▼]

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for less exposure of healthy tissue to higher radiation doses. However, evidence <br />issued from randomized trials is limited. European and American experts call our attention <br />to the potential dangers of widespread implementation of these techniques without any <br />long-term data on outcome and ask for complete information of patients on the potential <br />hazards and risks if accelerated partial breast irradiation is used instead of whole breast <br />irradiation. [less ▲]

Detailed reference viewed: 53 (8 ULg)
Full Text
Peer Reviewed
See detailLe cancer du sein en Belgique: pourquoi sommes-nous les premiers en Europe?
DESREUX, Joëlle ULg; Gaspard, Ulysse ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 231-7

Breast cancer incidence in Belgium is on the top of European countries, with 9.697 new cases in 2008 and 106/100.000 women/year. The explanation of this high incidence in our country is probably the ... [more ▼]

Breast cancer incidence in Belgium is on the top of European countries, with 9.697 new cases in 2008 and 106/100.000 women/year. The explanation of this high incidence in our country is probably the accumulation of risk factors (many of them are linked to lifestyle), and the impact of screening and registration of cases. The relative impact of each of theses factors is less clear because we don't have powerful statistical studies. Belgium is slightly above the European mean for breast cancer mortality, with 19,4/100.000 women/year and an all stages 15-year survival of 75%. Breast cancers are responsible for around 3% of all-cause mortality in Belgian women. This article discusses the causes of this high Belgian incidence and of current decrease of incidence in western countries, and reviews known and less known risk factors of breast cancers, with a special focus on menopause hormonal treatments. [less ▲]

Detailed reference viewed: 64 (3 ULg)
Full Text
Peer Reviewed
See detailReconstruction mammaire immédiate et radiothérapie post-opératoire : une mise au point
NARDELLA, Daniele ULg; LAUNGANI, Alexis ULg; LIFRANGE, Eric ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 368-361

La reconstruction mammaire est actuellement partie intégrante de la prise en charge du cancer du sein. Lorsqu’elle est proposée en immédiat, plusieurs contraintes se présentent au chirurgien plasticien ... [more ▼]

La reconstruction mammaire est actuellement partie intégrante de la prise en charge du cancer du sein. Lorsqu’elle est proposée en immédiat, plusieurs contraintes se présentent au chirurgien plasticien. La prise en charge des patientes devant bénéficier d’une mastectomie se complique par les traitements complémentaires de radiothérapie. Nous proposons, dans ce travail, une prise en charge multidisciplinaire des patientes en les adressant à des sous-groupes spécifiques. Une reconstruction immédiate sera proposée à certaines patientes compte tenu des traitements complémentaires par radiothérapie. Les choix d’orientation sont complexes et une littérature pauvre à ce sujet ne nous permet pas d’orienter de façon systématique toutes les patientes. De nouvelles études, notamment prospectives, sont nécessaires pour orienter les patientes désirant une reconstruction immédiate associée à une radiothérapie post-mastectomie. [less ▲]

Detailed reference viewed: 96 (0 ULg)
Full Text
Peer Reviewed
See detailLa chirurgie oncoplastique du sein.
BOUS, Aurélie ULg; NARDELLA, Daniele ULg; MAWEJA, Sylvie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 341-50

Oncoplastic surgery combines large lumpectomy and defect remodeling by different plastic surgery methods. These procedures improve the cosmetic result after partial mastectomy and widens the possibilities ... [more ▼]

Oncoplastic surgery combines large lumpectomy and defect remodeling by different plastic surgery methods. These procedures improve the cosmetic result after partial mastectomy and widens the possibilities for conservative treatment. Different techniques are used from simple glandular remodeling to more difficult techniques for breast plasties with or without simultaneous controlateral symetrisation procedure. The surgical option depends especially on the ratio between the volume of the tumor and the volume of the breast and the position of the tumor. This more effective conservative treatment facilitates also postoperative radiotherapy, reduces the sequellae and the psychological impact of breast cancer treatment. [less ▲]

Detailed reference viewed: 98 (7 ULg)
Full Text
Peer Reviewed
See detailPrise en charge des consequences de la carence oestrogenique apres cancer du sein.
BLERET, Valerie ULg; PINTIAUX, Axelle ULg; BELIARD, Aude ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 385-92

The prevention and the treatment of oestrogen deficiency induced by breast cancer treatments are crucial in the management of patients. The impacts of this deficiency must not be neglected: quality of ... [more ▼]

The prevention and the treatment of oestrogen deficiency induced by breast cancer treatments are crucial in the management of patients. The impacts of this deficiency must not be neglected: quality of life impairments inducing eventually premature withdrawal of hormonotherapies, and excess of bone and cardio-vascular morbidities and mortalities, especially in good prognosis young women. Management strategies of short and long term effects of this deficiency are reviewed and discussed here. [less ▲]

Detailed reference viewed: 62 (13 ULg)
Full Text
Peer Reviewed
See detailMastectomie bilaterale prophylactique chez les patientes a tres haut risque de cancer mammaire: au-dela de la technique...
BLERET, Valerie ULg; Cusumano, P.; DEZFOULIAN, Bahram ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 250-3

Bilateral prophylactic mastectomy is the most efficient risk management strategy for women at very high risk for breast cancer. Different methods can be used. The implementation of such a strategy must ... [more ▼]

Bilateral prophylactic mastectomy is the most efficient risk management strategy for women at very high risk for breast cancer. Different methods can be used. The implementation of such a strategy must respond to the request of a well informed patient. [less ▲]

Detailed reference viewed: 83 (7 ULg)
Full Text
Peer Reviewed
See detailGanglion sentinelle et sentibras: pour un "staging" axillaire sur mesure
Cusumano, P.; BLERET, Valerie ULg; Nos, C. et al

in Revue Médicale de Liège (2011), 66(5-6), 336-40

The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer. Histologic examination of removed lymph nodes is the most accurate method ... [more ▼]

The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer. Histologic examination of removed lymph nodes is the most accurate method for assessing spread of disease to these nodes. Axillary lymph node dissection (ALND) remains the standard approach for women who have clinically palpable axillary nodes. The benefits of ALND include its impact on disease control (axillary recurrence and survival), its prognostic value, and its role in treatment selection. However, the anatomic disruption caused by ALND may result in lymphedema, nerve injury, and shoulder dysfunction, which compromise functionality and quality of life. For patients who have clinically negative axillary lymph nodes, sentinel lymph node (SLN) biopsy offers a less morbid method to determine if there are positive nodes, in which case axillary node dissection would be necessary. Patients who are SLN-positive should undergo complete ALND. Axillary reverse mapping (ARM) is a recent improvement of ALND which, like the biopsy of the GS, would reduce morbidity. [less ▲]

Detailed reference viewed: 82 (6 ULg)
Full Text
Peer Reviewed
See detailLe cancer du sein de la femme âgée
MARTIN, Marie; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 400-408

Detailed reference viewed: 35 (1 ULg)
Full Text
Peer Reviewed
See detailLe cancer du sein chez la femme jeune
ANDRE, Chantal ULg; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 397-399

Detailed reference viewed: 83 (11 ULg)
Full Text
Peer Reviewed
See detailTraitements ciblés dans le cancer du sein
JERUSALEM, Guy ULg; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 379-384

Detailed reference viewed: 50 (8 ULg)
Full Text
Peer Reviewed
See detailPrise en charge et suivi d'une série consécutive de 411 patientes opérées pour cancer du sein
LIFRANGE, Eric ULg; ANDRE, Chantal ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 329-335

Detailed reference viewed: 40 (5 ULg)
Full Text
Peer Reviewed
See detailChimiothérapie et cancer du sein
COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg; MARTIN, M. et al

in Revue Médicale de Liège (2011), 66(5-6), 372-378

Detailed reference viewed: 63 (11 ULg)
Full Text
Peer Reviewed
See detailHormonothérapie du cancer du sein
LIFRANGE, Eric ULg; ANDRE, Chantal ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 367-371

Detailed reference viewed: 89 (18 ULg)
Full Text
Peer Reviewed
See detailL'observance au traitement de longue durée : le cas particulier de l'hormonothérapie adjuvante du cancer du sein
Bleret, Valerie ULg; Collignon, Joëlle ULg; Coucke, Philippe ULg et al

in Revue Médicale de Liège (2010), 65(5-6), 405-408

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité ... [more ▼]

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité démontrée de l'hormonothérapie, la compliance constitue un défi majeur et un problème multidimensionnel. Une meilleure compréhension des raisons de cette non-compliance aiderait à mieux identifier les patientes à risque et à développer des interventions capables d'améliorer l'adhésion à l'hormonothérapie adjuvante.C'est dans ce but que nous avons entrepris une revue de la littérature des six dernières années (Pub Med 2003-2006). [less ▲]

Detailed reference viewed: 139 (27 ULg)
Full Text
Peer Reviewed
See detailANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques
Collignon, Joëlle ULg; Gennigens, Christine ULg; Rorive, Andrée ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 279-83

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of ... [more ▼]

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of targeted therapies in subgroups of cancers. One of the first validation of targeted therapy is the anti-HER-2 monoclonal antibody trastuzumab (Herceptin) in patients with overexpression of human epidermal growth factor receptor type 2 (HER2) occurring in 20 to 25% of invasive breast carcinoma. Trastuzumab binds the extracellular juxtamembrane domain and is only active in tumor with HER2 gene amplification detected by fluorescence in situ hybridization (FISH). The results from randomized trials have rapidly lead to the approvement of the drug in the metastatic and then in the adjuvant setting. Another targeted therapy, also approved in the treatment of breast cancer, is the monoclonal antibody bevacizumab with an anti-VEGF (Vascular Endothelial Growth Factor) activity. We will review the benefit of these targeted therapies in breast cancer and their role in the treatment of breast cancer. [less ▲]

Detailed reference viewed: 387 (39 ULg)
Full Text
Peer Reviewed
See detailValidation de la technique de biopsie du ganglion sentinelle dans le cancer du sein
Bleret, Valerie ULg; Lifrange, Eric ULg; Ghuysen, Vincent ULg et al

in Revue Médicale de Liège (2008), 63(1), 37-42

PURPOSE: Assessment of our experience and validation of the sentinel lymph node biopsy technique in breast cancer stage T0-T2N0M0 surgery. METHODS: Identification and biopsy of the sentinel lymph node by ... [more ▼]

PURPOSE: Assessment of our experience and validation of the sentinel lymph node biopsy technique in breast cancer stage T0-T2N0M0 surgery. METHODS: Identification and biopsy of the sentinel lymph node by the radio colloid method in a consecutive series of 205 patients undergoing surgery for breast cancer stage T0-T2N0M0 between October 1998 and January 2007, initially in association with a complete axillary lymph node dissection (learning curve), later in an elective way. Prospective recording of the data and analysis with an average follow-up of 50 months (3 to 102 months). RESULTS: Biopsy rate of the sentinel lymph node of 90%, false negative rate of the method 2.5%, axillary recurrence rate 0%. CONCLUSION: We confirm in this series that the sentinel lymph node biopsy technique is a reliable approach in our experience for the evaluation of the axillary lymph node status in breast cancer stage T0-T2N0M0. [less ▲]

Detailed reference viewed: 11 (2 ULg)